Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis
Ann-Lii Cheng
Consultant or Advisory Role - Exelixis
Tim Meyer
Consultant or Advisory Role - Exelixis
Anthony B. El-Khoueiry
Consultant or Advisory Role - Exelixis (U)
Honoraria - Exelixis
Masafumi Ikeda
Consultant or Advisory Role - Exelixis
Hoo Geun Chun
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Sandrine J. Faivre
Honoraria - Exelixis
Research Funding - Exelixis
Junji Furuse
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Takuji Okusaka
Consultant or Advisory Role - Exelixis
Jerry Ping
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Anne E. Borgman-Hagey
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Robin Kate Kelley
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis